Nicki Thompson – BioLeader Interview
Nicki Thompson – BioLeader Interview
15 March 2022
PIR International – View full story
Nicki Thompson – BioLeader Interview
15 March 2022
PIR International – View full story
Biotech 2050: Novel Approach to Targeted Protein Degradation, Nicki Thompson, CEO, Amphista Therapeutics
01 February 2023
Biotech 2050 – View full story
‘The Top Line’: What makes the Fierce 15 honorees tick, Fierce Biotech Summit’s spotlight on gene editing and the bear market
30 September 2022
Amphista interview starts at 10:41
Fierce Pharma – View full story
Amphista Therapeutics opens Granta Park research facility
30 September 2022
Cambridge Independent – View full story
Amphista enters two collaborations for protein degrading therapeutics
6 May 2022
European Pharmaceutical Manufacturer – View full story
Amphista Lands Megadeals to Smash Cancer using Protein Degradation
6 May 2022
Heal Security – View full story
Amphista and BMS partner to develop protein degradation therapies
6 May 2022
Pharma Advancement – View full story
Ups And Downs In Protein Degraders: Big Deals For BMS, Merck KGaA, Safety Worries For Kymera
5 May 2022
Scrip – View full story
BMS, Merck Partner with Amphista Therapeutics to Develop Targeted Protein Degraders
5 May 2022
Precision Oncology News – View full story
Amphista and BMS partner to develop protein degradation therapies
5 May 2022
Pharmaceutical Technology – View full story